Loading…
Loading grant details…
| Funder | Wellcome Trust |
|---|---|
| Recipient Organization | Newcastle University |
| Country | United Kingdom |
| Start Date | Aug 12, 2024 |
| End Date | Aug 11, 2032 |
| Duration | 2,921 days |
| Number of Grantees | 1 |
| Roles | Award Holder |
| Data Source | Europe PMC |
| Grant ID | 306522 |
Disease caused by inherited mitochondrial (mt)DNA mutations is clinically heterogeneous; individuals carrying the same pathogenic variant can have very different phenotypic presentations and disease severity. This is exemplified by the most common heteroplasmic disease-causing variant, m.3243A>G. The precise pathogenic mechanisms of m.3243A>G remain elusive, creating a substantial knowledge gap.
My hypothesis is that m.3243A>G-disease is influenced by nuclear genetic and environmental factors that determine the cellular response to this variant.
This is further complicated by heteroplasmy: the presence of variable levels of wild-type and mutant mtDNA within the same cell.
I aim to exploit the natural cell-to-cell variability afforded by heteroplasmy, employing single-cell methods, population genetics and cell-models, to determine and define the drivers of disease associated with m.3243A>G.
I will: 1) Characterise the cellular response to m.3243A>G in patient cells with single-cell multiomics; 2) Identify nuclear genetic and environmental factors that contribute to disease within a large patient cohort; 3) Characterise nuclear factors using iPSC-derived disease-specific cell models.
Understanding disease heterogeneity associated with m.3243A>G is of paramount importance for patients and healthcare providers. Solving this holds the key to improving patient prognosis and developing targeted treatments. Furthermore, this investigation serves as a paradigm for comprehending other, rarer, mtDNA variants.
Newcastle University
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant